Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871467 · ClinicalTrials.gov registry record · Phase 1
Sargramostim for Myeloid Dendritic Cell Deficiency
A Phase 1 study of Dendritic Cell Deficiency, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT01871467: Completed Phase 1 study of Dendritic Cell Deficiency, sponsored by Johns Hopkins University.
NCT01871467 is a Phase 1 study of Dendritic Cell Deficiency that has completed, run by Johns Hopkins University. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01871467, a Phase 1 study of Dendritic Cell Deficiency, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell levels in patients with kidney disease in the hopes of developing new therapies to prevent viral infections after kidney transplantation.
Conditions Studied
Interventions
- DRUG Sargramostim
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT01871467 record still lists
NCT01871467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Dendritic Cell Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Sargramostim is the first listed.
NCT01871467 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01871467 about?
NCT01871467 is a clinical study titled "Sargramostim for Myeloid Dendritic Cell Deficiency". Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell levels in patients with kidn...
What is the current status of trial NCT01871467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-05. Estimated completion is 2014-06.
What conditions does trial NCT01871467 study?
This clinical trial studies the following conditions: Dendritic Cell Deficiency.
What interventions are being tested in trial NCT01871467?
The interventions under investigation include: Sargramostim (DRUG).
Who is sponsoring clinical trial NCT01871467?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01871467 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01871467's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia